INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41m ago
HOUSE PTR54s ago
SEC 13F47s ago
ROBINHOOD CHAIN43s ago
SEC FORM 4/Tax withholdingVerified data

Buck Kristen K reported LSTA

EVP, R&D and CMO · LISATA THERAPEUTICS, INC. · Common Stock

Side
F
Value
$6,345
Shares
3,221
Price
$1.97
Executed
Jan 9, 2026
Disclosed
Jan 13, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 9 executedJan 13, 2026 disclosed

LSTA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+1 / 25

$6K reported value · 3.5% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LSTA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    21
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    15.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$2,760
    1,401 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$1,655
    840 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$1,472
    747 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$1,011
    513 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    IT
    Imam TariqSVP, Bus Dev, General Counsel
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    7,000 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    21
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    15.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    13
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$4,198
    2,131 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    13
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$4,198
    2,131 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$2,240
    1,137 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$1,539
    781 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    NJ
    Nisco JamesSVP, Fin/Treas, Chief Actg Off
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    7,000 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    17
    BK
    Buck Kristen KEVP, R&D and CMO
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    25.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BK
    Buck Kristen KEVP, R&D and CMO
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$5,875
    2,982 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BK
    Buck Kristen KEVP, R&D and CMO
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$5,875
    2,982 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BK
    Buck Kristen KEVP, R&D and CMO
    LSTALISATA THERAPEUTICS, INC.
    Tax withholding
    		F$4,230
    2,147 sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BK
    Buck Kristen KEVP, R&D and CMO
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    13.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    17
    FL
    Flowers Cynthia LouiseDirector
    LSTALISATA THERAPEUTICS, INC.
    Grant or award
    		A—
    30.5K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001879231-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 9, 2026
    Published
    Jan 13, 2026
    Ingested by INSIDER
    Nov 5, 04:23 UTC
    Last re-read
    Nov 5, 04:23 UTC

    Extracted facts

    Filer
    Buck Kristen K
    Role
    EVP, R&D and CMO
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    LISATA THERAPEUTICS, INC.
    Ticker
    LSTA
    Shares
    3,221
    Price per share
    $1.97
    Value
    $6,345
    Execution date (reported)
    Jan 9, 2026
    Owned after transaction
    95.6K shares
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 3,221
    • Price: $1.97

    = $6,345

    What this establishes

    Buck Kristen K filed this Form 4 reporting a tax withholding of LSTA on Jan 9, 2026. It became public on Jan 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP, R&D and CMO
    Buck Kristen Kcik:0001879231
    Issuer
    LISATA THERAPEUTICS, INC.cik:0000320017

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.